Effects of an adrenal 11-beta, 17-alpha hydroxylase inhibitor in juvenile-onset diabetes mellitus.
D015065:17-Hydroxycorticosteroids / Q000097:blood / Q000652:urine; D015068:17-Ketosteroids / Q000652:urine; D000293:Adolescent; D000311:Adrenal Glands / Q000201:enzymology*; D000324:Adrenocorticotropic Hormone / Q000494:pharmacology; D000328:Adult; D003480:Cushing Syndrome / Q000188:drug therapy; D003922:Diabetes Mellitus, Type 1 / Q000188:drug therapy*; D005260:Female; D005951:Glucose Tolerance Test; D006801:Humans; D008297:Male; D008875:Middle Aged; D006899:Mixed Function Oxygenases / Q000037:antagonists & inhibitors*; D010627:Phenethylamines / Q000494:pharmacology*; D011188:Potassium / Q000652:urine; D012964:Sodium / Q000652:urine; D013256:Steroids / Q000652:urine
D015065:17-Hydroxycorticosteroids; D015068:17-Ketosteroids; D010627:Phenethylamines; D013256:Steroids; D000324:Adrenocorticotropic Hormone; D012964:Sodium; D006899:Mixed Function Oxygenases; D011188:Potassium